IQVIA Holdings Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022
April 27, 2022 at 07:00 am EDT
Share
IQVIA Holdings Inc. provided earnings guidance for the second quarter and full year of 2022. For full-year 2022, the company's expectation of low-to-mid teens organic revenue growth at constant currency, excluding COVID-related work, remains unchanged. To reflect the impact of the strengthening of the USD, as well as to a lesser extent, some disruption from the Ukraine/Russia crisis, the company is updating its revenue guidance range. The company now expects revenue to be between $14,450 million and $14,750 million, representing growth of 6.9 to 9.0% at constant currency, and 4.2 to 6.3% on a reported basis.
For the second quarter of 2022, the company expects revenue to be between $3,470 million and $3,520 million, representing growth of 4.5 to 6.0% at constant currency and 0.9 to 2.4% on a reported basis, with underlying organic revenue growth excluding COVID-related work of low-to-mid teens at constant currency.
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:
- development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
- integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).